This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ueno, T. Articles by Tominaga, T. Search for Related Content PubMed PubMed Citation Articles by Ueno, T. Articles by Tominaga, T.

Circulating Soluble Fas Concentration in Breast Cancer Patients

Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo 113-0021, Japan

Fas/Fas ligand (FasL) system, a major regulator of apoptosis, is involved in cancer cell death induced by the immune system and anticancer drugs. Fas is a cell-surface receptor that exists in two forms, transmembrane and soluble. The former induces apoptosis by ligation of FasL or agonistic anti-Fas antibody, whereas the latter inhibits Fas-mediated apoptosis by neutralizing its ligand. In this study, we examined circulating soluble Fas (sFas) concentration in 118 healthy people, 162 primary and 71 recurrent breast cancer patients by ELISA. In the healthy group, men showed higher sFas concentrations than women (P < 0.001). In both sexes, sFas levels increased with age, and the age-matched cutoff value was determined. The median sFas concentration in primary and recurrent cancer patients was 0.815 and 1.510 ng/ml, both of which were higher than in normal female controls (0.580 ng/ml; P = 0.024 and P < 0.001, respectively). Among primary cancer patients, although no significant correlation was found between sFas concentration and clinical parameters other than menopausal status, high-sFas patients had a worse prognosis than low-sFas patients for both overall and disease-free survival (P = 0.013 and P = 0.032, respectively). The multivariate analysis confirmed that circulating sFas concentration was an independent prognostic indicator (P = 0.020 for overall survival, P = 0.025 for disease-free survival). We looked at the recurrent cancer patients, and sFas levels were higher in patients with liver metastasis compared with those with other recurrent sites (P = 0.010), and high-sFas patients showed a worse prognosis than low-sFas patients (P = 0.037). Our data demonstrate that, compared with healthy female controls, breast cancer patients, especially those with liver metastases, have higher circulating sFas levels. sFas may be useful once these results are confirmed by larger studies.

This article has been cited by other articles:

				G. Onalan, B. Selam, Y. Baran, M. Cincik, R. Onalan, U. Gunduz, A. U. Ural, and R. Pabuccu Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF Hum. Reprod., September 1, 2005; 20(9): 2391 - 2395. [Abstract] [Full Text] [PDF]

				A. Malamitsi-Puchner, A. Sarandakou, S. Baka, N. Vrachnis, E. Kouskouni, and D. Hassiakos Soluble Fas Concentrations in the Follicular Fluid and Oocyte-Cumulus Complex Culture Medium From Women Undergoing In Vitro Fertilization: Association With Oocyte Maturity, Fertilization, and Embryo Quality Reproductive Sciences, December 1, 2004; 11(8): 566 - 569. [Abstract] [PDF]

				C. D. Albright, R. I. Salganik, and T. Van Dyke Dietary Depletion of Vitamin E and Vitamin A Inhibits Mammary Tumor Growth and Metastasis in Transgenic Mice J. Nutr., May 1, 2004; 134(5): 1139 - 1144. [Abstract] [Full Text] [PDF]

				L. Owen-Schaub Soluble Fas and Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1108 - 1109. [Full Text]

				S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased Soluble CD95 (sFas/CD95) Serum Level Correlates with Poor Prognosis in Melanoma Patients Clin. Cancer Res., May 1, 2001; 7(5): 1282 - 1286. [Abstract] [Full Text]